Manitex Capital, Inc.

  • Market Cap: Micro Cap
  • Industry: Investment Managers
  • ISIN: CA56342H2000
CAD
0.07
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

0

Shareholding (Jun 2023)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Investment Managers

stock-summary
Market cap

CAD 1 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

-5.45%

stock-summary
Price to Book

0.13

Revenue and Profits:
Net Sales:
(Quarterly Results - Jul 2024)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-44.44%
0%
-44.44%
6 Months
-66.67%
0%
-66.67%
1 Year
-64.29%
0%
-64.29%
2 Years
-87.29%
0%
-87.29%
3 Years
-86.61%
0%
-86.61%
4 Years
-91.85%
0%
-91.85%
5 Years
-68.09%
0%
-68.09%

Manitex Capital, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
14.29%
EBIT to Interest (avg)
-0.49
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.13
EV to EBIT
-0.80
EV to EBITDA
-0.80
EV to Capital Employed
0.11
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.14%
ROE (Latest)
-5.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jul 2024 is 0.00% vs 0.00% in Jul 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jul 2024 is -1,100.00% vs 107.69% in Jul 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "0.20",
          "chgp": "-600.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "0.10",
          "chgp": "-1,100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2023 is 0.00% vs 0.00% in Oct 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2023 is 104.11% vs -87.18% in Oct 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'23",
        "Oct'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-0.90",
          "chgp": "55.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "0.20",
          "chgp": "300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.30",
          "val2": "-7.30",
          "chgp": "104.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'24 - YoYstock-summary
Jul'24
Jul'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
0.00
-0.00
Interest
0.00
0.00
Exceptional Items
-1.00
0.20
-600.00%
Consolidate Net Profit
-1.00
0.10
-1,100.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Jul 2024 is 0.00% vs 0.00% in Jul 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jul 2024 is -1,100.00% vs 107.69% in Jul 2023

Annual Results Snapshot (Consolidated) - Oct'23stock-summary
Oct'23
Oct'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.40
-0.90
55.56%
Interest
0.00
0.00
Exceptional Items
0.80
0.20
300.00%
Consolidate Net Profit
0.30
-7.30
104.11%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Oct 2023 is 0.00% vs 0.00% in Oct 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Oct 2023 is 104.11% vs -87.18% in Oct 2022

stock-summaryCompany CV
About Manitex Capital, Inc. stock-summary
stock-summary
Manitex Capital, Inc.
Investment Managers
Manitex Capital Inc. is a Canada-based company that specializes in acquiring interests in companies and participates in increasing shareholder value in these businesses. The Company operates through three segments: diversified investments (investment), biotechnology (biotech) and a pharmaceutical business (pharma). The investment segment holds interests in companies in the life science industry and also invests in marketable securities. Through its subsidiary, ANRis Pharmaceuticals Inc. (ANRis), (the biotechnology segment), the Company specializes in development of the delivery of nucleic acids for therapeutic purposes. Through its subsidiary, Valeo Pharma Inc. (Valeo), (the pharmaceutical segment), the Company acquires and markets specialty pharmaceutical products and also markets and distributes third-party pharmaceutical products. VPI Pharmaceuticals Inc. is the subsidiary of the Valeo.
Company Coordinates stock-summary
Company Details
16667 Hymus Blvd , KIRKLAND QC : H9H 4R9
stock-summary
Tel: 1 514 6938830
stock-summary
stock-summary
Registrar Details